Please wait while the formulary information is being retrieved.
Drug overview for GLUCERNA HUNGER SMART (nutritional therapy, glucose intolerance,lactose-free,soy):
Generic name: nutritional therapy, glucose intolerance,lactose-free,soy
Drug class:
Therapeutic class: Electrolyte Balance-Nutritional Products
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
Generic name: nutritional therapy, glucose intolerance,lactose-free,soy
Drug class:
Therapeutic class: Electrolyte Balance-Nutritional Products
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for GLUCERNA HUNGER SMART (nutritional therapy, glucose intolerance,lactose-free,soy) have been approved by the FDA:
Indications:
None.
Professional Synonyms:
None.
Indications:
None.
Professional Synonyms:
None.
The following dosing information is available for GLUCERNA HUNGER SMART (nutritional therapy, glucose intolerance,lactose-free,soy):
No enhanced Dosing information available for this drug.
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for GLUCERNA HUNGER SMART (nutritional therapy, glucose intolerance,lactose-free,soy):
There are 0 contraindications.
There are 0 severe interactions.
There are 2 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Selected Quinolones/Enteral Nutrition SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Absorption of orally administered quinolones may be decreased with concurrent enteral nutrition administration. CLINICAL EFFECTS: Administration of a quinolone during enteral nutritional therapy may result in a decrease in clinical effect of the quinolone as a result of lower serum and urine levels. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Quinolone blood levels should be carefully monitored if the patient is receiving concurrent enteral nutrition. An alternate antibiotic agent may need to be considered. DISCUSSION: In a study, concurrent administration of ciprofloxacin, levofloxacin, and ofloxacin with Ensure resulted in average decreases in quinolone serum levels of 82.5%, 61.3% and 45.7% respectively.(1) In another study, concurrent Ensure reduced the percent of relative bioavailability of ciprofloxacin significantly more than ofloxacin.(2) In a study in 26 hospitalized patients, administration of ciprofloxacin via jejunostomy tube with an enteral formula decreased ciprofloxacin mean bioavailability by 67%.(3) Conversely, a study showed that ciprofloxacin is well absorbed after administration via a nasogastric tube in the presence of enteral feeding compared with an orally administered tablet.(4) Gatifloxacin administration with concomitant gastric tube feeding did not affect gatifloxacin bioavailability, but critical illness resulted in significant variability in bioavailability.(5) Conversely, administration with Ensure significantly decreased gatifloxacin maximum concentration (Cmax) by 44.6%, time to reach Cmax (Tmax) by 60%, area-under-curve (AUC) by 26.2%, and relative oral bioavailability by 26%.(6) In a study, the oral bioavailability of moxifloxacin administered as a crushed tablet was not affected by concomitant enteral feeding through a nasogastric tube.(7) The relative bioavailability of temafloxacin was not affected by enteral nutrition.(8) |
BAXDELA, CIPRO, CIPROFLOXACIN, CIPROFLOXACIN HCL, GATIFLOXACIN SESQUIHYDRATE, LEVOFLOXACIN, OFLOXACIN |
| Thyroid Preparations/Soybean Infant Formula; Nutritional Therapy SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Soy-based formula and nutritional therapy may bind to thyroid preparations, decreasing their absorption.(1-3) Also, many products may contain iron, which may also bind to thyroid preparations.(1) CLINICAL EFFECTS: Concurrent use of soy-based formula or nutritional therapy may result in increased TSH levels.(1-3) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Patients receiving soy-based formula or nutritional therapy should be closely monitored for elevated TSH levels. The dosage of the thyroid preparation may need to increase during the use of soy-based products.(1-3) DISCUSSION: In a retrospective comparison of 78 infants with congenital hypothyroidism, 8 infants fed a soy-based formula had prolonged increase of TSH and time to TSH normalization, higher first TSH on treatment, and there was a larger percentage with increased TSH at 4 months of age when compared to 70 infants on a non-soy diet.(2) In a case report of 3 infants with congenital hypothyroidism, infants required 18-25% higher dosages of levothyroxine while receiving soy-based formulas.(3) In a case report, the administration of levothyroxine concurrently with a soy protein dietary supplement resulted in decreased absorption of levothyroxine and the need for higher oral doses of levothyroxine to attain therapeutic serum thyroid hormone levels.(4) |
ADTHYZA, ARMOUR THYROID, CYTOMEL, ERMEZA, EUTHYROX, LEVO-T, LEVOTHYROXINE SODIUM, LEVOXYL, LIOTHYRONINE SODIUM, NIVA THYROID, NP THYROID, PCCA T3 SODIUM DILUTION, RENTHYROID, SYNTHROID, THYQUIDITY, THYROID, TIROSINT, TIROSINT-SOL, UNITHROID |
The following contraindication information is available for GLUCERNA HUNGER SMART (nutritional therapy, glucose intolerance,lactose-free,soy):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 0 severe contraindications.
There are 0 moderate contraindications.
The following adverse reaction information is available for GLUCERNA HUNGER SMART (nutritional therapy, glucose intolerance,lactose-free,soy):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 0 severe adverse reactions.
There are 0 less severe adverse reactions.
The following precautions are available for GLUCERNA HUNGER SMART (nutritional therapy, glucose intolerance,lactose-free,soy):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for GLUCERNA HUNGER SMART (nutritional therapy, glucose intolerance,lactose-free,soy):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for GLUCERNA HUNGER SMART (nutritional therapy, glucose intolerance,lactose-free,soy)'s list of indications:
No ICD codes found for this drug.
No ICD codes found for this drug.
Formulary Reference Tool